UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Presentations<br />
Efficacy and hematologic toxicity of carboplatin and talazoparib<br />
combination therapy in BRCA mutated patients.<br />
Authors*: Mallika Sachdev Dhawan, Rahul Raj Aggarwal, Imke Bartelink, Jim Leng, Scott Thomas,<br />
Nela Pawlowska, Laurie Stevenson, Amy Jo Chien, Robin Kate Kelley, Julia Clennell, Pamela N. Munster<br />
Abstract #: 2557<br />
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #257<br />
Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2557)<br />
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of<br />
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved<br />
in clinical and translational research in early phase clinical trials since 1998. As the program leader for<br />
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating<br />
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies<br />
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on<br />
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition<br />
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification<br />
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
*<strong>UCSF</strong> authors in bold<br />
49
Change language